Core Viewpoint - Haier Biomedical (688139.SH) announced a share reduction plan by its shareholder, Qingdao Haichuangrui Equity Investment Fund Center, due to funding needs, intending to reduce up to 0.85% of its total shares, equating to a maximum of 2,690,189 shares [1] Group 1 - Haichuangrui plans to reduce its holdings in Haier Biomedical through centralized bidding, with a reduction period starting 15 trading days after the announcement and lasting for three months [1] - As of the last trading day before the announcement, Haier Biomedical's share price was 33.34 yuan per share, estimating the reduction amount to be approximately 89.69 million yuan [1] - Haichuangrui currently holds 32,103,659 shares of Haier Biomedical, representing 10.14% of the total share capital [1] Group 2 - Haichuangrui has signed a voting rights entrustment agreement with Haier Group, establishing a concerted action relationship [2] - Haier Group, through its controlled entity, Qingdao Haier Biomedical Medical Holdings, holds 100,591,463 shares, accounting for 31.78% of Haier Biomedical's total shares [2] - Another concerted action partner, Qingdao Haichuangzhi Management Consulting Enterprise, holds 8,675,900 shares, representing 2.74% of the total shares [2] Group 3 - Haier Biomedical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2019, after receiving approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [3] - The company issued a total of 79,267,940 shares at a price of 15.53 yuan per share, raising approximately 1.23 billion yuan, with actual funds received amounting to about 1.16 billion yuan [3] - The funds were verified by Ernst & Young Hua Ming and were received on October 22, 2019, with Guotai Junan Securities serving as the lead underwriter [3]

Core Viewpoint - The "Haier system" is rapidly expanding its capital footprint, with Kaos IoT Technology Co., Ltd. submitting its application for an IPO on the Hong Kong Stock Exchange, following Haier New Energy's A-share listing guidance [1][11] Group 1: Company Performance - Kaos reported steady revenue growth, achieving approximately CNY 4.994 billion in 2023 and CNY 5.069 billion in 2024, with a net profit turnaround from a loss of CNY 82.72 million in 2023 to a profit of CNY 65.14 million in 2024 [3][13] - For the first three quarters of 2025, Kaos generated approximately CNY 4.421 billion in revenue, up from CNY 3.635 billion in the same period the previous year, with a profit of approximately CNY 176 million, significantly higher than the CNY 35.71 million from the previous year [3][13] Group 2: Dependency on Haier Group - Haier Group is the largest customer of Kaos, contributing over 57.7% of the company's revenue in the first three quarters of 2025, with sales to Haier amounting to CNY 2.549 billion [4][14] - The proportion of sales to the top five customers was approximately 69.7% in 2025, with Haier's contribution being CNY 3.607 billion in 2023, CNY 3.421 billion in 2024, and CNY 2.549 billion in 2025 [4][14] Group 3: Market Position and Strategy - Kaos is positioned as a leading provider of industrial data intelligence solutions in China, ranking first in the market based on platform revenue for 2024 [2][12] - The decision to pursue a listing on the Hong Kong Stock Exchange follows challenges faced in attempting to list on the STAR Market, where regulatory scrutiny and lengthy approval processes were significant factors [2][12] Group 4: Capital Expansion - The Haier Group has established a capital structure that spans both A-share and H-share markets, currently comprising eight listed entities, with the potential to increase to ten if both Kaos and Haier New Energy successfully complete their IPOs [1][11][18] - The total market capitalization of Haier's listed companies exceeds CNY 330 billion, with Haier Smart Home leading at CNY 235.472 billion [17][18]

Core Viewpoint - The Haier Group is expanding its capital footprint with the recent IPO applications of its subsidiaries, Kaos and Haier New Energy, aiming to increase the number of listed companies under its umbrella to ten if both IPOs are successful [1][12]. Group 1: Company Performance - Kaos has shown steady performance improvement, with revenues of approximately RMB 4.994 billion in 2023 and RMB 5.069 billion in 2024, and a projected net profit turnaround from a loss of RMB 82.72 million in 2023 to a profit of RMB 65.14 million in 2024 [4]. - For the first three quarters of 2025, Kaos reported revenues of about RMB 4.421 billion, up from RMB 3.635 billion in the same period the previous year, with a corresponding profit of approximately RMB 176 million, significantly higher than the RMB 35.71 million from the previous year [4]. Group 2: Dependency on Haier Group - Haier Group is the largest customer of Kaos, contributing 57.7% of its revenue in the first three quarters of 2025, with sales to Haier amounting to RMB 25.49 billion [6]. - The sales to the top five customers accounted for approximately 69.7% of Kaos's revenue in the same period, indicating a high dependency on a limited customer base [6]. Group 3: Market Position and Strategy - Kaos is positioned as a leading provider of industrial data intelligence solutions in China, ranking first in the market based on projected revenue for 2024 [3]. - The decision to pursue a listing on the Hong Kong Stock Exchange instead of the Sci-Tech Innovation Board is seen as a strategic move to avoid stringent regulatory pressures associated with the latter [3][4]. Group 4: Capital Expansion - The Haier Group has established a capital structure that spans both A-share and H-share markets, currently comprising eight listed companies with a total market value exceeding RMB 330 billion [9]. - If Kaos and Haier New Energy successfully complete their IPOs, the number of listed companies under Haier Group will increase to ten, further solidifying its market presence [12].

证券代码：688139 证券简称：海尔生物 公告编号：2026-005 青岛海尔生物医疗股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 股东持股基本情况 2.为严格履行公司回购股份方案中关于回购股份使用期限的相关承诺，同时增强投资者回报能力和水平， 切实维护广大投资者利益，公司将第一次回购计划存放于回购专用账户中的 1,459,586 股已回购股份用途 由"用于员工持股计划或股权激励"变更为"用于注销并相应减少注册资本"并已于 2026 年 1 月 6 日注销 完成。 2 青岛海创睿股权投资基金中心（有限合伙）（以下简称"海创睿"）持有青 岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）32,103,659 股，占公司总股本的 10.14%。该股份属于公司首次公开发行前取得的股份，截 至本公告披露日，上述股东所持股份均已上市流通。 海创睿与公司实际控制人海尔集团公司（以下简称"海尔集团"）签署了《表 决权委托协议》，构成一致行动关系。此外，海尔 ...

Core Viewpoint - Haier Bio received a notice from Haichuang Rui regarding a share reduction plan due to its own funding needs, indicating a potential impact on the company's stock performance [1] Group 1: Share Reduction Plan - Haichuang Rui plans to reduce its shareholding in Haier Bio through centralized bidding, with a maximum reduction of 0.85% of the total share capital, equivalent to no more than 2,690,189 shares [1] - The reduction period is set to begin 15 trading days after the announcement of this reduction plan and will last for three months [1] - The reduction price will be determined based on market prices [1]

证券代码：688139 证券简称：海尔生物 公告编号：2026-005 青岛海尔生物医疗股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 股东持股基本情况 青岛海创睿股权投资基金中心（有限合伙）（以下简称"海创睿"）持有青 岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）32,103,659 股，占公司总股本的 10.14%。该股份属于公司首次公开发行前取得的股份，截 至本公告披露日，上述股东所持股份均已上市流通。 海创睿与公司实际控制人海尔集团公司（以下简称"海尔集团"）签署了《表 决权委托协议》，构成一致行动关系。此外，海尔集团还通过其控制的青岛海尔 生物医疗控股有限公司（以下简称"海尔生物医疗控股"）以及一致行动人青岛 海创智管理咨询企业（有限合伙）（以下简称"海创智"）分别持有公司股份 100,591,463 股和 8,675,900 股，占公司总股本的 31.78%、2.74%。 海尔集团一致行动人海创智分别于 2022 年 3 月、2 ...

海尔生物公告，持股10.14%的股东青岛海创睿股权投资基金中心（有限合伙）因资金需求，拟通过集 中竞价方式减持不超过269.02万股，占公司总股本0.85%，期限为2026年3月3日至2026年6月2日；其现 持有3210.37万股，均为IPO前取得股份。截至公告披露日，实际控制人及一致行动人合计持股1.41亿 股，占44.67%，自上市以来未减持公司股份，减持计划不会导致控制权变更。 ...

（来源：淘金ETF） 2026年1月20日，国家疾控局联合国家发改委、财政部、国家卫生健康委等六部委正式印发《疾病预防 控制领域强基实施方案》（国疾控规财发〔2026〕3号），锚定2027、2030两大阶段目标，以"基础补短 板、设备标准化、数智化升级"为核心抓手，全面部署疾控体系强基工程；1月27日公开发布，政策红利 正式释放，万亿级公共卫生设备市场需求被激活，医疗器械板块迎来政策驱动下的设备更新与产业升级 黄金机遇期。 核心痛点亟待破解，政策精准施策 当前我国疾控体系仍面临"资源不均、设备滞后、数智薄弱"三大痛点——基层医疗机构基础诊疗设备普 及率，大量设备超期服役，中西部县域疾控设备达标率低；疾控资源80%集中在城市高端医疗机构，县 域及乡镇疾控"硬件""软件"双重薄弱；传统监测预警、流调溯源依赖人工，数智化应用未覆盖基层末 梢。与此同时，人口老龄化推升慢性病防控压力，公共卫生应急响应对设备标准化、数智化的要求持续 升级，筑牢基层疾控网底成为"健康中国"建设的关键一环。本次六部委从印发到公开发布的密集动作， 正是瞄准这些核心痛点的精准施策，既是落实中央经济工作会议"医疗卫生强基工程"的关键举措，更是 为 ...

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

Core Viewpoint - Haier Biomedical aims to become a world-class brand in life sciences trusted by global users, with a focus on expanding its business internationally and enhancing its industry presence [1] Group 1: Business Expansion - The company has expanded its operations to over 150 countries and regions worldwide [1] - Localized deployments have been established in 18 countries [1] - Revenue from overseas markets now accounts for more than 35% of total income [1] Group 2: Strategic Focus - Haier Biomedical is committed to a strategy of both organic growth and external acquisitions within the life sciences sector [1] - The company plans to identify high-quality targets in the life sciences industry to strengthen its existing operations and broaden its business scope [1] - There is an emphasis on entering high-potential market segments [1]